Predictive Oncology Inc. (POAI)
| Market Cap | 32.88M |
| Revenue (ttm) | 1.48M |
| Net Income (ttm) | -26.96M |
| Shares Out | 80.19M |
| EPS (ttm) | -0.31 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 90,395 |
| Open | 0.429 |
| Previous Close | 0.435 |
| Day's Range | 0.410 - 0.443 |
| 52-Week Range | 0.249 - 1.466 |
| Beta | 1.36 |
| Analysts | Buy |
| Price Target | 5.46 (+1,231.7%) |
| Earnings Date | Aug 9, 2022 |
About POAI
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, a... [Read more...]
Financial Performance
In 2021, POAI's revenue was $1.42 million, an increase of 13.45% compared to the previous year's $1.25 million. Losses were -$19.66 million, -24.06% less than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for POAI stock is "Buy." The 12-month stock price forecast is 5.46, which is an increase of 1,231.71% from the latest price.
News
Predictive Oncology Reports Second Quarter 2022 Financial Results
EAGAN, Minn., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) today announced the financial results for its second quarter ended June 30, 2022, which shows a strong balance she...
Traders News Source Senior Editor Mark Roberts Interviews J. Melville Engle, CEO and Chairman of the Board, Predictiv...
NEW YORK, NY / ACCESSWIRE / August 9, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap publicly traded companies recently issued a...
Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansi...
EAGAN, Minn., July 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced a strategic move to further strengthen its business and product offerings by appointing Julia Kirshner,...
Predictive Oncology Announces Closing of $7.2 Million Registered Direct Offerings
EAGAN, Minn., May 18, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
Predictive Oncology Announces $7.2 Million Registered Direct Offerings
EAGAN, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“...
Predictive Oncology Reports First Quarter Financial Results
EAGAN, Minn., May 12, 2022 (GLOBE NEWSWIRE) -- The financial results from the first quarter we believe depicts a solid potential for growth in the upcoming period, in accordance with the report by Predi...
Marketer with over 20 years of experience selected to head up marketing at Predictive Oncology
EAGAN, Minn., April 26, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (NASDAQ: POAI) today announced that Theresa Ferguson has been named Senior Director of Marketing. As Predictive Oncology's senior mar...
Predictive Oncology Reports Year End 2021 Financial Results and Provides Business Update
EAGAN, Minn., March 31, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug disco...
Predictive Oncology validates Discovery 21 proof-of-concept campaign
Predictive Oncology's Discovery 21 campaign evaluated the ability of its PeDAL® platform to make high-confidence predictions in ovarian tumor samples. Subsequent validation confirmed the accuracy and re...
Predictive Oncology set to market AI drug discovery platform
MINNEAPOLIS, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) is set to be a first mover in the artificial intelligence (AI) powered drug discovery market that POAI expects will...
POAI Reports Strong Results From Its AI Cancer Drug Evaluation
MINNEAPOLIS, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) reported the preliminary results of its Discovery 2021 program today, announcing that its Helomics subsidiary's eva...
Predictive Oncology Adjourns Annual Meeting of Stockholders to December 30, 2021
MINNEAPOLIS, Dec. 27, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...
Predictive Oncology Inc. (POAI) Upgraded to Buy: What Does It Mean for the Stock?
Predictive Oncology Inc. (POAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Predictive Oncology – Year-end Shareholder Update!
EAGAN, Minn., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology , (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, is mov...
Pamela Bush, Ph.D., MBA, Joins Predictive Oncology as SVP of Strategic Sales and Business Development
Bush to lead Predictive Oncology's novel sales effort towards cancer research technologies Bush to lead Predictive Oncology's novel sales effort towards cancer research technologies
Predictive Oncology Acquires zPREDICTA, Inc.
zPREDICTA has developed a patented tumor-specific 3D cell culture platform that is complementary to Predictive Oncology's Artificial Intelligence (AI) platform developed by Helomics. zPREDICTA's uniquel...
Predictive Oncology Inc. (POAI) Reports Q3 Loss, Misses Revenue Estimates
Predictive Oncology Inc. (POAI) delivered earnings and revenue surprises of 20.00% and -82.56%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the s...
Predictive Oncology Reports Third Quarter Financial Results
EAGAN, Minn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Results from the third quarter show strong potential for future growth, said Predictive Oncology (Nasdaq: POAI) today, announcing financial results for th...
Predictive Oncology Inc. (POAI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Predictive Oncology Inc. (POAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Predictive Oncology Launches Website Highlighting AI-Powered Cancer Research Advancements
Predictive Oncology is leveraging AI to streamline drug discovery and development, improve outcomes in clinical testing and forge a new frontier of cancer research Predictive Oncology is leveraging AI t...
Predictive Oncology Announces Results of Charter Amendment Proposal at Special Meeting
MINNEAPOLIS, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...
Predictive Oncology Reports Financial Results for Quarter Ended June 30, 2021, and Provides Business Update
MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...
Predictive Oncology Adjourns Special Meeting of Stockholders
MINNEAPOLIS, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discove...
Predictive Oncology subsidiary, Helomics uses data from the 100,000 Genomes Project to better predict ovarian cancer ...
Initial results demonstrate that AI models of genomic data can predict cancer outcomes. This has the potential to help personalize ovarian cancer treatments and drive the discovery of new therapies. Ini...